Huakang Biomedical Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Huakang Biomedical Holdings şirketinin kazançları yıllık ortalama -1.2% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 14.7% oranında artan oldu. Gelirler yıllık ortalama 0.8% oranında artan oldu.

Anahtar bilgiler

-1.2%

Kazanç büyüme oranı

0.6%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	13.7%
Gelir büyüme oranı	0.8%
Özkaynak getirisi	-10.8%
Net Marj	-24.3%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Gelir ve Gider Dağılımı

Huakang Biomedical Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SEHK:8622 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	25	-6	20	3
31 Mar 24	25	-6	21	3
31 Dec 23	25	-6	20	3
30 Sep 23	24	-5	19	3
30 Jun 23	25	-4	19	3
31 Mar 23	25	-3	19	3
31 Dec 22	25	-3	19	2
30 Sep 22	26	-2	18	3
30 Jun 22	26	-3	18	3
31 Mar 22	27	-4	18	3
31 Dec 21	26	-4	18	2
30 Sep 21	26	-7	18	2
30 Jun 21	27	-8	19	2
31 Mar 21	25	-10	21	2
31 Dec 20	22	-12	21	2
30 Sep 20	21	-9	21	2
30 Jun 20	21	-7	20	2
31 Mar 20	22	-3	18	2
31 Dec 19	25	0	16	2
30 Sep 19	26	-3	16	2
30 Jun 19	27	-2	14	2
31 Mar 19	28	0	12	1
31 Dec 18	29	0	11	1
31 Dec 17	27	-2	6	1
31 Dec 16	25	8	5	1
31 Dec 15	19	8	4	2

Kaliteli Kazançlar: 8622 şu anda kârlı değil.

Büyüyen Kar Marjı: 8622 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 8622 kârlı değildir ve zararlar son 5 yılda yılda 1.2% oranında artmıştır.

Büyüme Hızlandırma: 8622 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 8622 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( -4.3% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 8622 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -10.81% ) sahiptir.

Huakang Biomedical Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023)

Huakang Biomedical Holdings Company Limited to Report First Half, 2024 Results on Aug 16, 2024

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Recent updates

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023)

Huakang Biomedical Holdings Company Limited to Report First Half, 2024 Results on Aug 16, 2024

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin